NCT00591526View on ClinicalTrials.gov

A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions
Leukemia, Promyelocytic, Acute
Interventions
DRUG

Arac

Ommit ARAC in the chemotherapy

All Listed Sponsors
collaborator

University Hospital, Lille

OTHER

lead

Groupe d'etude et de travail sur les leucemies aigues promyelocytaires

OTHER

NCT00591526 - A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL) | Biotech Hunter | Biotech Hunter